Valuation: Novacyt

Market Cap 36.9M 43.07M 34.58M 31.59M 59.61M 4.11B 60.2M 408M 159M 2.07B 162M 158M 6.86B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 38.86M 45.35M 36.41M 33.26M 62.77M 4.32B 63.39M 430M 167M 2.18B 170M 167M 7.22B EV / Sales 2026 *
1.27x
EV / Sales 2027 * 1.2x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-0.59%
1 week-6.30%
Current month+25.40%
1 month+13.45%
3 months-12.31%
6 months+28.26%
Current year+38.63%
1 week 0.49
Extreme 0.4865
0.53
1 month 0.4
Extreme 0.4035
0.54
Current year 0.29
Extreme 0.293
0.97
1 year 0.29
Extreme 0.293
0.97
3 years 0.29
Extreme 0.293
1.39
5 years 0.29
Extreme 0.293
5.8
10 years 0.04
Extreme 0.0429
13.78
Manager TitleAgeSince
Chief Executive Officer 53 01/05/2024
Director of Finance/CFO 44 01/01/2020
Chief Operating Officer - 01/11/2021
Director TitleAgeSince
Director/Board Member 75 03/07/2006
Director/Board Member 60 27/06/2017
Director/Board Member 44 02/01/2024
Change 5-day change 1-year change 3-year change Capi.($)
-0.59%-6.30% - - 43.07M
+1.64%0.00%-38.70%-41.35% 633M
+2.81%-8.80%+82.76% - 344M
-7.13%-2.58%-36.21%-9.46% 127M
-2.02%-2.51%-20.49%+22.78% 77.56M
Average -1.06%-2.94%-3.16%-9.34% 295.42M
Weighted average by Cap. +0.75%-0.86%-1.85%-30.57%

Financials

2026 *2027 *
Net sales 30.52M 35.62M 28.6M 26.13M 49.31M 3.4B 49.79M 337M 131M 1.71B 134M 131M 5.67B 34.86M 40.68M 32.67M 29.84M 56.31M 3.88B 56.87M 385M 150M 1.96B 153M 149M 6.48B
Net income - -
Net Debt 1.96M 2.28M 1.83M 1.67M 3.16M 218M 3.19M 21.62M 8.42M 110M 8.57M 8.38M 364M 4.84M 5.65M 4.54M 4.14M 7.82M 539M 7.9M 53.52M 20.83M 272M 21.22M 20.75M 900M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change
26/08/26 EUR 0.5060 -0.20%
25/08/26 EUR 0.5070 -3.61%
24/08/26 EUR 0.5260 +3.95%
21/08/26 EUR 0.5060 -0.59%
20/08/26 EUR 0.5090 -5.74%

Annual profits - Rate of surprise